Shots:

• The P-II TRUST trial evaluates taletrectinib (AB-106- ROS1/NTRK inhibitor) in 37 TKI-naïve or pre-treated patients with ROS1-positive NSCLC
• As of June 16- 2021 cut off data- the therapy demonstrated an ORR (90.5% & 43.8%) & DCR (90.5% & 75.0%) in treatment-naïve & pre-treated patient. ROS1 G2032R resistant mutations were observed in three pre-treated patients & experienced tumor regression- 2 patients reported PR & 1 patient achieved SD
• Additionally- patients with assessable brain metastasis pre-enrollment demonstrated intracranial ORR (83.3%) as assessed by the investigator. The therapy was safe with well- tolerated AEs

| Ref: PR Newswire | Image: Innovent